Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a 7/8 or 8/8 HLA A, B, C and DR, HLA-matched related donor willing and able to donate allogeneic stem cells.~* For patients with multiple myeloma, CLL, and lymphoma: must be in CR, PR, or stable disease.~* For MDS, acute leukemia or CML: must have \<20% blasts on marrow exam.~* For all other diseases: must have non-refractory disease.~and meet at least ONE of the next three criteria:~* Any patient ≥ 18 years of age with a hematological malignancy and not considered a candidate for allogeneic myeloablative transplant due to illness and/or age (≥55 years).~* Any patient ≥ 18 years of age who has relapsed following prior autologous or allogeneic transplant for a hematologic malignancy.~* Any patient ≥ 18 years of age diagnosed with a hematological malignancy for which reduced intensity transplant is institutionally preferred over myeloablative transplant (eg, chronic lymphocytic leukemia).~Exclusion Criteria:~* Less than 18 years of age.~* Currently taking any HDAC inhibitors, or have taken an HDAC inhibitor within 30 days of the trial.~* Positive serum tests for HIV, HTLV1 / HTLV2.~* Detectable hepatitis B virus (HBV), hepatitis C (HCV) or Epstein-Barr (EBV).~* Pregnancy.~* One or more of the following organ system function criteria~  * Cardiac: Ejection fraction ≤ 40%~ * Renal: Estimated or actual GFR ≤ 40 ml/min (corrected for BSA)~ * Pulmonary: FEV1, FVC, or DLCO ≤ 40% predicted~ * Hepatic: Total bilirubin ≥3 mg% and AST/ALT \>5 x institutional normal for age~ * Karnofsky score ≤50 (Requires considerable assistance and frequent medical care).~* Persistent invasive infections not controlled by antimicrobial medication.~* Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat prophylaxis (Type: EXPERIMENTAL): Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).